Merck & Co., Inc. recently terminated discussions to acquire Revolution Medicines after talks stalled over a roughly $30 billion valuation. According to those familiar with the matter, Merck’s decision underscores its continued discipline on deal size despite strong interest in bolstering its oncology portfolio through RAS-pathway assets. Investors interpreted the news as a sign that Merck remains cautious about overpaying for high-growth targets, leading to a modest share price pullback.

In the latest regulatory filings, Cullen Frost Bankers reduced its Merck holding by 7.0%, selling 17,082 shares and bringing its position to 225,581 shares, valued at approximately $18.9 million. Meanwhile, Charles Schwab Investment Management increased its stake by 9.4%, acquiring over 4.6 million shares during the quarter, and Norges Bank and DLD Asset Management each initiated positions valued at roughly $2.86 billion and $2.89 billion, respectively. Overall, institutional ownership remains robust at just over 76%.

Merck enters the period with a solid liquidity profile: a current ratio of 1.66, a quick ratio of 1.44 and a debt-to-equity ratio of 0.77. The company announced a quarterly dividend of $0.85 per share, up from $0.81, representing a 3.1% yield on an annualized basis and a payout ratio near 45%. These metrics reflect Merck’s commitment to returning capital to shareholders while maintaining investment capacity for R&D and strategic opportunities.

A consensus of 17 analysts currently rates Merck at a Hold, with eight Buy ratings, seven Holds and two Sells. Average price targets stand at $114.20, ranging from $82.00 to $135.00. Notably, BMO Capital Markets and Wolfe Research upgraded their outlooks to Outperform earlier this quarter, citing stable cash flows from established products and continued pipeline momentum, particularly in oncology and vaccines.